FDA Issues Draft Guidance on Early Solid Tumor Trials

The draft guidance covers first-in-human studies for solid tumor investigational drugs and biologics, with public comments due January 11, 2027.

Updated on Nov. 11, 2026 in Cancer

FDA Issues Draft Guidance on Early Solid Tumor Trials

The U.S. Food and Drug Administration issued draft guidance on early-phase first-in-human studies for investigational drugs and biologics targeting solid tumors. The guidance does not cover protocols for hematologic malignancies.

Why it matters

The guidance supports Operation TrialBlazer, an HHS initiative launched in mid-June 2026 as a pilot to reverse the trend of clinical development shifting away from the United States. It addresses eligibility, dose escalation, dose expansion, Phase 2 dose selection, companion diagnostics, and data analysis.

The draft guidance is open for public comment through January 11, 2027, under docket FDA-2026-D-13432 on regulations.gov. The extraction does not provide trial outcome statistics or comparative efficacy figures tied to the guidance.

The players

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating drugs, biologics, and medical devices in the United States, and the issuer of this draft guidance.

U.S. Department of Health and Human Services (HHS)

The federal department overseeing public health programs, which launched Operation TrialBlazer to maintain U.S. leadership in early clinical research.

The details

The guidance states that overly restrictive eligibility criteria may impede patient recruitment, and that protocols should generally avoid upper age limits. It says the primary objective of a first-in-human dose escalation trial should be assessing safety and tolerability, and that single-arm trials do not adequately characterize overall survival or progression-free survival, with randomized designs generally needed for time-to-event endpoints.

Mid-June 2026: Operation TrialBlazer launched by HHS and FDA.
November 11, 2026: FDA draft guidance published and reported.
January 11, 2027: Public comment deadline for the draft guidance.

Roadmap

The guidance is the regulatory follow-through on Operation TrialBlazer, a pilot aimed at reversing the trend of early clinical development moving outside the United States. By setting explicit design expectations for solid tumor first-in-human studies, FDA is translating that policy goal into specific trial requirements.

Patients with solid tumors may see broader trial eligibility if sponsors adopt the guidance's advice against overly restrictive criteria and upper age limits. Comments can be submitted at regulations.gov under docket FDA-2026-D-13432 before the January 11, 2027 deadline.

The takeaway

Sponsors and patients alike should watch how the final guidance treats eligibility and randomization for solid tumor trials. Stakeholders who want to influence the outcome have until January 11, 2027 to comment.